Premium
The selective cyclooxygenase‐2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria
Author(s) -
Boehncke WH.,
J.Ludwig R.,
M.Zollner T.,
Ochsendorf F.,
Kaufmann R.,
F.Gibbs B.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2003.05209_12.x
Subject(s) - rofecoxib , medicine , desloratadine , antihistamine , thromboxanes , histamine , cyclooxygenase , angioedema , aspirin , mast cell , prostaglandin d2 , systemic mastocytosis , allergy , histamine h1 antagonists , pharmacology , prostaglandin , immunology , thromboxane , chemistry , platelet , enzyme , biochemistry